Literature DB >> 6984805

Cytochrome P-450 metabolic-intermediate complex formation and induction by macrolide antibiotics; a new class of agents.

L K Pershing, M R Franklin.   

Abstract

1. By several criteria, macrolide antibiotics constitute a new class of nitrogenous cytochrome P-450 metabolic-intermediate complex-forming compounds. 2. Macrolide antibiotic metabolic-intermediate complexes are only formed in livers induced with phenobarbital or with the macrolide antibiotics themselves. The extent of metabolic-intermediate complex formation in microsomes from phenobarbital-induced rats is lower than that seen for members of the amphetamine and SKF 525-A classes of compounds. 3. Cytochrome P-450 induced by macrolide antibiotics, of which troleandomycin is the most potent, is extensively sequestered as a metabolic intermediate complex in vivo. 4. Cytochrome P-450 induced by troleandomycin differs, using several criteria, from those induced by phenobarbital, beta-naphthoflavone or SKF 525-A, and those present in uninduced rats.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6984805     DOI: 10.3109/00498258209038944

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  9 in total

1.  Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir.

Authors:  Irina F Sevrioukova; Thomas L Poulos
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-11       Impact factor: 11.205

2.  Cytochrome P-450 metabolic-intermediate complex formation from p-aminobenzoic acid esters and other arylamines.

Authors:  Z Liu; M R Franklin
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Apr-Jun       Impact factor: 2.441

3.  Cytochrome P-450 complex formation by dirithromycin and other macrolides in rat and human livers.

Authors:  T D Lindstrom; B R Hanssen; S A Wrighton
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

4.  Upregulation of cytochromes P450 2B in rat liver by orphenadrine.

Authors:  Michael Murray; Eva Fiala-Beer; Dylan Sutton
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

5.  Human cytochrome P450 3A4: enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase.

Authors:  M S Shet; C W Fisher; P L Holmans; R W Estabrook
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

Review 6.  Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions.

Authors:  Jaydeep Yadav; Erickson Paragas; Ken Korzekwa; Swati Nagar
Journal:  Pharmacol Ther       Date:  2019-12-11       Impact factor: 12.310

Review 7.  Pharmacokinetic interactions of the macrolide antibiotics.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1985 Jan-Feb       Impact factor: 6.447

8.  Cytochrome P-450 metabolic-intermediate complex formation with a series of diphenhydramine analogues.

Authors:  A Bast; A J Valk; H Timmerman
Journal:  Agents Actions       Date:  1990-04

Review 9.  Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.

Authors:  Shufeng Zhou; Sui Yung Chan; Boon Cher Goh; Eli Chan; Wei Duan; Min Huang; Howard L McLeod
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.